Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs.The company is set to capture 50% of the $95 billion obesity market by 2050.We got a glimpse into Eli ...

Key Points Rhythm Pharmaceuticals' lone approved product currently generates minimal sales.However, recent clinical progress ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

New public and private entrants are emerging to challenge the leading positions of Novo Nordisk and Eli Lilly in a potential $200 billion total GLP-1 market, which we expect will see 68% of sales ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a promising ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

On June 23, Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend of $1.50 per share, which was in line with its ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Shares of Eli Lilly & Co. LLY rallied 1.34% to $771.71 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,296.79 and ...

Eli Lilly continues to find ways to fend off the increasingly stiff competition in this market. Several companies are working on oral formulations of GLP-1 therapies. Others are looking into long ...

Half of the year is over! So, which pharmaceutical giant outpaces the others? Sharp investors wonder whose market capitalization has risen farthest? Whose ...